Journal
Journal of Clinical Oncology
Publication Date
7-10-2024
Volume
42
Issue
20
First Page
2404
Last Page
2414
Document Type
Open Access Publication
DOI
10.1200/JCO.23.01684
Rights and Permissions
Van Tine BA, Ingham MA, Attia S, Meyer CF, Baird JD, Brooks-Asplund E, D'Silva D, Kong R, Mwatha A, O'Keefe K, Weetall M, Spiegel R, Schwartz GK. Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma. J Clin Oncol. 2024 Jul 10;42(20):2404-2414. doi: 10.1200/JCO.23.01684. © 2024 by American Society of Clinical Oncology. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/
Recommended Citation
Van Tine, Brian A; Ingham, Matthew A; Attia, Steven; Meyer, Christian F; Baird, John D; Brooks-Asplund, Esther; D'Silva, Dhiren; Kong, Ronald; Mwatha, Anthony; O'Keefe, Kylie; Weetall, Marla; Spiegel, Robert; and Schwartz, Gary K, "Phase Ib study of unesbulin (PTC596) plus dacarbazine for the treatment of locally recurrent, unresectable or metastatic, relapsed or refractory leiomyosarcoma." Journal of Clinical Oncology. 42, 20. 2404 - 2414. (2024).
https://digitalcommons.wustl.edu/oa_4/4113
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
